Pharma BD Deal Intelligence

AstraZeneca PLC / CSPC Pharmaceutical Group Ltd.

2025 · Licensing/Option · $5.3B · Complete

AstraZeneca entered a strategic research collaboration with CSPC Pharmaceutical Group to use CSPC's AI-driven small molecule discovery platform to identify pre-clinical candidates for high-priority targets, including an oral small molecule for immunological diseases. CSPC receives $110 million upfront and is eligible for up to $1.62 billion in development milestones and up to $3.6 billion in sales milestones plus single-digit royalties; AstraZeneca holds an option to exclusively license and commercialize candidates globally.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  AstraZeneca PLC deals